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Nitric oxide (NO) is a potent dilator of vascular smooth muscle (VSM) by modulating intracel-
lular cGMP ([cGMP]i) through the binding and activation of receptor guanylyl cylases (sGC).
The kinetic relationship of NO and sGC, as well as the subsequent regulation of [cGMP]i and
its effects on blood vessel vasodilation, is largely unknown. In isolated VSM cells exposed
to both pulsed and clamped NO we observed transient and sustained increases in [cGMP]i,
with sub-nanomolar sensitivity to NO (EC50=0.28 nM). Through the use of pharmacologi-
cal inhibitors of sGC, PDE5, and PKG, a comprehensive VSM-specific modeling algorithm
was constructed to elucidate the concerted activity profiles of sGC, PDE5, phosphorylated
PDE5, and PDE1 in the maintenance of [cGMP]i. In small pressure-constricted arteries
of the resistance vasculature we again observed both transient and sustained relaxations
upon delivery of pulsed and clamped NO, while maintaining a similarly high sensitivity
to NO (EC50=0.42 nM). Our results propose an intricate dependency of the messengers
and enzymes involved in cGMP homeostasis, and vasodilation inVSM. Particularly, the high
sensitivity of sGC to NO in primary tissue indicates how small changes in the concentra-
tions of NO, irrespective of the form of NO delivery, can have significant effects on the
dynamic regulation of vascular tone.
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INTRODUCTION
Nitric oxide (NO) is produced in small puffs by the nitric oxide
synthase of endothelial cells (eNOS), which diffuses into vascu-
lar smooth muscle (VSM) and acts directly on the NO-sensitive
guanylyl cyclases α1β1/α2β1 (Arnold et al., 1977; Moncada et al.,
1991a; Lowenstein and Michel, 2006). The resulting synthesis of
cyclic-3′,5′-guanosine monophosphate (cGMP) is critical in medi-
ating vasodilation through activation of cGMP-dependent protein
kinase (PKG), which subsequently lowers intracellular calcium
(Waldman and Murad, 1987; Sausbier et al., 2000; Schlossmann
et al., 2000; Friebe and Koesling, 2003).
The short biological half-life of NO (Griffith et al., 1984; Cocks
et al., 1985; Hakim et al., 1996; Wood et al., 2011) has previously
served to explain the transient in nature of NO-induced vasore-
laxation (Ignarro et al., 1987, 1988; Palmer et al., 1987; Amezcua
et al., 1988; Moncada et al., 1991b). However, the kinetics of the
NO/cGMP/PKG signaling mechanism has not yet been described
in VSM. It has been recently shown that the coupling of NO
donors to the NO-scavenger CPTIO alters the kinetics of NO as
to deliver a sustained application of NO, which can be modeled to
determine NO concentration, previously confirmed by NO elec-
trode (Bellamy et al., 2002; Griffiths et al., 2003). This approach
allowed for the direct vascular response to NO to be determined
without interference of NO decay. Combination of this NO deliv-
ery method with the single wavelength cGMP biosensor, FlincG
(Nausch et al., 2008), has recently been described as an exceedingly
sensitive NO detector in intact cells, using cGMP as a gauge of sGC
activity (Batchelor et al., 2010; Wood et al., 2011). Sub-nanomolar
concentrations of NO were detected, albeit dependent on sGC
expression level, providing insight into the mechanism for the bio-
logical effects of NO at very low concentrations (Batchelor et al.,
2010). While this cellular model provides invaluable insight into
the NO-dependent activation of sGC, a generalization to all types
of mammalian tissues remains controversial. Particularly VSM
cells appear to harbor their unique sets of regulatory enzymes
in the maintenance of cGMP homeostasis.
A model has also been developed to predict the activities of sGC
and phosphodiesterases (PDEs), the two main enzymes involved
in cGMP maintenance, in platelets and cerebellar astrocytes (Mon-
cada et al., 1991a; Conti et al., 1995; Francis et al., 2001; Derbyshire
and Marletta,2009; Halvey et al., 2009; Kemp-Harper and Schmidt,
2009). This approach provided an intimate view into the enzy-
matic control of cGMP production and degradation in platelets
and astrocytes. Through a modification of the original model we
could determine the activity of endogenous sGC to NO and the
level of phosphodiesterases involved in smooth muscle cells of the
vasculature.
Here we have found a very high sensitivity to NO in iso-
lated VSM cells as compared to other endogenous sGC activities
reported, conforming to a low expression level of sGC. Through
the use of the cGMP biosensor δ-FlincG, the regulation of NO-
induced [cGMP]i was determined to be through the concerted
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actions of sGC and PDEs in VSM cells. Likewise, the low EC50 for
NO was confirmed in pressurized arteries from the resistance vas-
culature, suggesting the regulation of cGMP directly transcends
to the control of vasodilation. This two-pronged in vitro and ex
vivo approach enabled us to establish of the endogenous kinetic
inter-relationship of NO, [cGMP]i, and vasodilation at physiolog-
ically relevant NO concentrations, specific for SM tissue of the
vasculature.
EXPERIMENTAL PROCEDURES
MATERIALS
The NO donors: DEA/NO, DETA/NO, MAHMA/NO, Sper-
mine/NO, and PROLI/NO were purchased from Cayman Chem-
ical (Ann Arbor, MI, USA). 2-(4-carboxyphenyl)-4,5-dihydro-
4,4,5,5-tetramethyl-1H-imidazol-1-yloxy-3-oxide (CPTIO) and
1H-[1,2,4] Oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). DT-2 was
synthesized by Dr. Jose Madalengoitia’s laboratory. Hank’s Bal-
anced Salt Solution (HBSS), DMEM, and penicillin/streptomycin
were purchased from Mediatech (Manassas, VA, USA) and Bovine
Growth Serum (BGS) was from Hyclone (Logan, UT, USA). Col-
lagenase Type 2 and Elastase were from Worthington Biochemical
(Lakewood, NJ, USA).
VASCULAR SMOOTH MUSCLE CELL CULTURE
Smooth muscle cells from the thoracic aorta of Sprague-Dawley
rats were digested, dissociated, and plated on Delta T4 dishes
(Bioptechs, Butler, PA, USA) as previously described (Cawley et al.,
2007). Cells were minimally cultured (without passaging) before
overnight transfection with 85µL 107–109/mL titer adenoviral
δ-FlincG (Nausch et al., 2008) and imaged on the fourth day,
unless stated otherwise. Adenoviral constructs were propagated
and maintained according to manufacturer’s instructions (Invit-
rogen). All animal studies and procedures were approved by the
Institutional Animal Care and Use Committee at the University of
Vermont.
FLUORESCENCE IMAGING OF cGMP IN VSM CELLS
Live-cell, epi-fluorescent microscopy was performed as previ-
ously described (Nausch et al., 2008) in imaging buffer [10 mM
TES (pH 7.4), 1 g/L d-glucose, HBSS] using a Nikon Diaphot
200 microscope outfitted with a Nikon x40/1.30 oil objective,
mercury-halide lamp (X-CITE 120; EXFO Photonics, Toronto)
and a cooled charge-coupled device camera (ORCA ER; Hama-
matsu, Japan) capturing one image per 3 s. Confocal imaging
was executed on a Nikon E600SN microscope adapted with an
Andor spinning disk confocal system, 60× water dipping objec-
tive (N.A. 1.0) and iXon ENCCD DVB camera set to acquire
five images per second with a 64 ms exposure to a 488 nm
solid-state laser. Emission above 510 nm was collected for mea-
surements. Both microscopes used the Delta T4 open culture
system to maintain 37˚C for the duration of the experiments.
NO donors and ODQ stocks were made fresh on the day of
use. All compounds were added directly to the imaging buffer
and mixed by careful pipetting to avoid cell disturbances and
movement. Confocal data analysis was conducted with custom-
written software (SparkAn) developed by Dr. Adrian Bonev, while
epi-fluorescent analysis was performed using Metafluor version
6.2 software (Universal Imaging, Media, PA, USA; Nausch et al.,
2008). All FlincG traces are represented as the ratio of fluores-
cence signal intensity and background fluorescence (F/F0). The
mean value reported is a composite of traces from several indi-
vidual cells digested from multiple aortas. Cellular movement
during the course of the experiment was accounted for during
analysis. Several small regions of throughout the cell were drawn
with imaging software and repositioned if necessary to obtain flu-
orescent quantifications. A cell is represented by the average of
these regions. Dose-response curves were calculated with Graph-
Pad Prism software (version 5.04) for each individual experiment,
and then averaged to obtain the mean and standard deviation
values.
MATHEMATICAL MODELING OF NO AND cGMP CONCENTRATIONS,
PDE AND sGC ACTIVITY
The NO delivery model was developed through differential equa-
tions based on the chemical reactions for NO release from
NONOate donors and NO consumption by CPTIO and O2, as pre-
viously described (Griffiths et al., 2003; Roy and Garthwaite, 2006).
Tandem to these calculations, formulations for sGC activity were
described using the following equations, based on the model of
NO binding to the heme of sGC (Halvey et al., 2009). PDE5 activ-
ity was solved for by assuming cGMP hydrolysis via four states
of the enzyme: unliganded (PDE5, PDE5a), cGMP-bound inac-
tive (cGMP-PDE5, PDE5b), cGMP-bound active (cGMP-PDE5,
PDE5c), and phosphorylated (cGMP-P-PDE5∗, PDE5d) from the
following model [adapted from (Halvey et al., 2009)]:
kp1 Kp2 Kp3
PDE5  cG−PDE 5  cG−PDE 5∗  cG−P−PDE 5∗
Vp1 kp−1 Vp1 kp−2 Vp2 kp−3 Vp3
Kp1 Kp1 Kp2 Kp3
(1)
Activation rates are represented in lower case italicized letters,
while catalysis rates are capitalized and italicized in Eq. 1 and
below. The rate of cGMP synthesis by NO-activated sGC is repre-
sented by v1(t) and PDE1 activity is denoted as Vpx and affinity
as Kpx .
The rates are described by the following equations:
d
dt
G (t ) = v1 (t )− PDE5a (t ) · Vp1 · G (t )
Kp1 + G (t )
− PDE5b (t ) · Vp1 · G (t )
Kp1 + G (t )
− PDE5c (t ) · Vp2 · G (t )
Kp2 + G (t )
− PDE5d (t ) · Vp3 · G (t )
Kp3 + G (t ) −
Vpx · G (t )
Kpx + G (t )
(2)
d
dt
PDE5a (t ) = kp−1 · PDE5b (t )− kp1 · PDE5a (t ) · G (t ) (3)
d
dt
PDE5b (t ) = kp1 · PDE5a (t ) · G (t )− kp−1 · PDE5b (t )
+ kp−2 · PDE5c (t )− kp2 · PDE5b (t ) (4)
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d
dt
PDE5c (t ) = kp2 · PDE5b (t )− kp−2 · PDE5c (t )
+ kp−3 (t ) · PDE5d (t )
− kp3 · G (t ) · PDE5c (t ) (5)
d
dt
PDE5d (t ) = kp3 ∗ PDE5c (t )− kp−3 ∗ PDE5d (t ) (6)
where G denotes cGMP concentration. All differential equations
were solved using the Adams/BDF and adaptive Runge–Kutta algo-
rithms in Mathcad (see Supplementary Material; version 14.0;
Parametric Technology Corporation, Needham, MA, USA). The
velocity and rate constants for the inactive and active NO and
cGMP receptors (sGC, PDE5, P-PDE5, and PDE1, respectively),
were determined assuming G(0)= 4.16 nM, PDE5a(0)= 0.8,
PDE5b(0)= 0, PDE5c(0)= 0, and PDE5d(0)= 0.2 at time zero.
Values from previously studies (Vp1, Kp1, Kp2,Vp3, Kp3,Vpx, and
Kpx; see Table 3) and as determined (GCmax and Vp2) were calcu-
lated by the Levenberg-Marquardt method of least squares curve
fitting of the proposed model to actual data using the MinErr
function of MathCad, as shown in the Supplementary Material
and previously described (Wood et al., 2011). The resulting values
were then combined to determine the velocity of cGMP hydrolysis
(Vd) by solving:
Vd (t ) = PDE5a (t ) · Vp1 · G (t )
Kp1 + G (t ) + PDE5b (t ) ·
Vp1 · G (t )
Kp1 + G (t )
+ PDE5c (t ) · Vp2 · G (t )
Kp2 + G (t ) + PDE5d(t ) ·
Vp3 · G (t )
Kp3 + G (t )
+ Vpx · G (t )
Kpx + G (t ) (7)
The FlincG response to the total calculated cGMP concentration
was also modeled based on the binding affinity of cGMP for δ-
FlincG (170 nM; Nausch et al., 2008) using the following equation:
FG (t ) =
[
Rmax ∗ G(t )p
G(t )p + (0.17 ∗ 10−6)p
]
(8)
where FG(t) is the predicted FlincG response, Rmax is the maxi-
mal percent response of the indicator, and p is the Hill coefficient
1.45, as determined from the cGMP binding curves (Nausch et al.,
2008). The final algorithm was compiled using the averaged calcu-
lated MinErr values for each of the NONOate donors simulated.
MYOGRAPHY
Anterior cerebral arteries from male Sprague-Dawley rat and third
order mesenteric arteries from male mice (∼100µm starting
diameter) were isolated and cannulated in physiological saline
solution (PSS; 119 mM NaCl, 4.7 mM KCl, 24 mM NaHCO3,
1.2 mM KH2PO4, 0.03 mM EDTA, 1.2 mM MgSO4, 1.6 mM
CaCl2, 10.6 mM glucose, pH 7.4 at 4˚C) as previously described in
a DMT organ culture myograph (Danish Myo Technology A/S).
Warmed (37˚C) and gassed (20% O2/5% CO2/75% N2) PSS was
circulated through the myograph chamber and arterial diam-
eters were measured using edge detection software (VediView,
DMT; Nickl et al., 2010). Intraluminal pressure was progressively
increased in 20 mmHg steps using a pressure manometer to allow
for the development of myogenic tone (usually between 60 and
80 mmHg) before each experiment. Arterial viability was tested
with 60 mM KCl (less than 30% constriction were discarded), and
maximal (passive) arterial diameter was obtained for each artery
by Ca2+-free PSS containing EGTA (2 mM) at the end of each
experiment. The NO-scavenger CPTIO was added to the reservoir
and allowed to equilibrate before the addition of each NO donor.
Donors were added to either the circulating PSS reservoir or the
mounting chamber with similar results. Blue-dyed PSS was used
to measure the time required for compounds in the reservoir to
reach the myograph chamber for kinetic calculations (100 s). The
mean value for each experiment refers to separate applications
of NO to multiple individual arteries. EC50 values were calculated
with GraphPad Prism software for each individual artery, and then
averaged to obtain mean and standard deviation values.
RESULTS
KINETIC PROFILES OF NO AND cGMP IN VSM CELLS
First, we addressed the kinetic nature of intracellular cGMP in pri-
mary, δ-FlincG-transfected rat aortic VSM cells to either pulsed
(transient) or clamped (sustained) NO profiles by combining
NONOate donors with the NO-scavenger, CPTIO (Griffiths et al.,
2003). The short half-life donors, PROLI-NO, MAHMA-NO, and
DEA-NO (Table 1), gave rise to transient pulses of NO (Figures 1A
and 2A,B). Importantly, these transient decreases in cGMP were
observed in the absence of buffer washouts to terminate NO expo-
sure, indicating the rate of NO loss was directly dictated by the
NO donor half-life. The maximal or peak NO concentrations
for each donor were individually calculated based on the rates
of NO release as previously described (Griffiths et al., 2003). As
shown in Figure 1A, single applications of 200 nM MAHMA/NO
in the presence of 50µM CPTIO gave rise to NO pulses with
set peak concentrations of 5 nM (blue trace). The corresponding
biosensor responses indicating (cGMP)i (red trace) were equally
transient in nature, although we observed a slight lag in the timing
of the cGMP responses (2 s vs. 156 s for MAHMA/NO and Sper-
mine/NO, respectively). In contrast, when NO delivery was altered
to a clamped pattern using the long half-life donor Spermine-NO
(8+ 60µM CPTIO) the resulting 5 nM NO plateau was echoed
by a sustained cGMP profile (Figure 1B). To ensure the addi-
tion of CPTIO does not affect cGMP sub-cellular localization,
Table 1 | NO donor and cGMP kinetics.
Donor t1/2 (s) NO P1/2 (s) cGMP P1/2 (s) τ (s) n
PROLI/NO 1.8 4.5 26.7±7.7 23±6.2 9
MAHMA/NO 63 73 135±9.4 75±8.8 11
DEA/NO 126 145 206±11.3 99±8.1 10
Spermine/NO 2,340 n/a n/a n/a 12
DETA/NO 72,000 n/a n/a n/a 7
Summary table of the NO donor half-life (t1/2), the NO peak width at half-maximal
stimulation (NO P1/2), as well as the cGMP peak width at half-maximum (cGMP
P1/2), cGMP peak decay rate (τ) asmeasured by δ-FlincG, and number of replicates
is given for each NO donor.Values are represented as mean± standard deviation.
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FIGURE 1 | NO delivery and [cGMP]i profiles are correlated in
isolated FlincG-transfected VSM cells. Application of 5 nM of NO was
applied to VSM cells, resulting in transient or sustained [cGMP]i (blue
line, modeled NO concentration; red line, F/F0 averaged FlincG measured
cGMP). (A) MAHMA/NO (n=8), (B) Spermine/NO (n=9). Distribution of
[cGMP]i in response to NO, both transient (C) and sustained (D), is
globally dispersed throughout the cytoplasm (60× magnification, see
Methods).
FIGURE 2 | Kinetic correlation of pulsed NO and [cGMP]i. Short
half-life donors result in rapid NO (blue lines, modeled NO concentration)
and cGMP peaks (averaged traces, red lines, n=6) as depicted in (A;
PROLI/NO) and (B; DEA/NO). (C) Relationship between NO and cGMP
transients as measured by P 1/2 (r2 =0.9820, p<0.0001 by one-way
ANOVA).
δ-FlincG-transfected VSM cells were imaged by live-cell, fluores-
cence confocal microscopy. Both the pulsed and clamped condi-
tions (Figures 1C,D) exhibited global distribution, ensuring the
addition of the NO-scavenger does not alter the spatial pattern-
ing of [cGMP]i in accordance with previous results (Nausch et al.,
2008).
To further examine the inter-relationship of cGMP and NO
kinetics, two additional donors (PROLI/NO and DEA/NO) with
widely varying half-lives (Table 1), were used to generate corre-
sponding profiles of NO transients (Figures 2A,B). Analysis of the
kinetic parameters (cGMP peak widths and NO dissociation con-
stants) for each donor (PROLI/NO, MAHMA/NO, and DEA/NO),
revealed that the cGMP and NO peaks followed a linear correlation
(r2= 0.9820; Figure 2C). These results further indicate a strong
dependency of intracellular cGMP dynamics on the NO release
pattern.
ENDOGENOUS sGC IS HIGHLY SENSITIVE TO NO IN VSM CELLS
By exploiting the steady-state properties of Spermine/NO, addi-
tive clamped NO in fixed concentrations (0.05–25 nM) were used
to elicit distinct step-wise increases of [cGMP]i (Figure 3A). This
procedure allowed us to raise cGMP in progressive increments to
extrapolate a direct EC50 for sGC activation, as well as illustrate
maximal activation, and elucidate any potential indicator satu-
ration to ensure an accurate representation of sGC activity. The
fluorescence intensity (F/F0) was normalized for each NO step to
the maximal fluorescence response elicited by NO (25 nM). The
resulting dose-response relationship delivered an EC50 value of
0.28± 0.01 nM (Figure 3B, n= 11). This high sensitivity is com-
parable to low sGC-transfected HEK cells (GClowPDEHEK) used
as NO reporter cells previously reported (Batchelor et al., 2010;
Wood et al., 2011). Likewise, this value shows an approximate
threefold increase in potency than that previously reported in
platelets and astrocytes (Wykes and Garthwaite, 2004; Roy et al.,
2008). The additive steps of NO reach maximal cGMP produc-
tion by 2µM, which corresponds with the detection limitation of
δ-FlincG (Nausch et al., 2008).
To confirm that this low EC50 is not an artifact of a maximally
stimulated biosensor, our minimally cultured cells (4 days, unpas-
saged, see Methods, n= 11; shown in Figure 3B) were cultured
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FIGURE 3 | Sensitivity of sGC to steady-state NO in VSM cells. (A)
Representative FlincG trace of step-wise concentrations of clamped NO in
VSM cells. (B) NO dose-response curve derived from (A; n= 11). (C) EC50
curves derived from traces of VSM cells cultured for 4 days (closed circles),
6 days (open circles), and 4 day cultured, Angiotensin II-treated cells (1µM,
diamonds).
for an additional 48 h and exhibited a shift of the EC50 to ∼1 nM
(Figure 3C, n= 12). This shift demonstrates that the biosensor
has not saturated at 1 nM NO (Figure 3B) for the 4 day cultured
VSM cells, and the measured EC50 values are a valid indication of
NO-stimulated sGC production of cGMP and not an artifact of
the cGMP binding characteristics of δ-FlincG. To address whether
this shift was a result of oxidative stress, possibly due to two addi-
tional days of ambient air (20% O2) exposure, we activated an
endogenous mechanism for inducing oxidative stress, Angiotensin
II (1µM, 1–2 h; Griendling et al., 1994; Nakamura et al., 1998).
VSM cells cultured for 4 days and treated with Angiotensin II
resulted in a shift similar to the 6 day cultured cells (Figure 3C,
n= 13). Therefore, sGC sensitivity is not hindered by the usage
of δ-FlincG, and the control of cell culture conditions is a vital
component to studying cellular NO.
THE CONCERTED ACTIONS OF BOTH sGC AND PDE5 CONTRIBUTE TO
[cGMP]I IN VSM CELLS
While sGCα1/β1 is known to produce [cGMP]i upon NO activa-
tion, it is not known if sGC activity will remain elevated through-
out a sustained application of NO in VSM cells, or if it rapidly
desensitizes as in platelets and neurons in the continued presence
of NO (Arnold et al., 1977; Moncada et al., 1991a; Bellamy et al.,
2000; Bellamy and Garthwaite, 2001; Kass et al., 2007). Repeated
applications of NO in the presence (Figures 4A,B) and absence
(Cawley et al., 2007; Nausch et al., 2008) of CPTIO resulted in
stable reproducible increases in [cGMP]i, with little decrease in
their amplitudes, suggesting modest sGC desensitization, and a
decrease in sGC activity after NO decay. To determine the duration
of sGC activation, the sGC inhibitor, ODQ, was administered in
the presence of sustained NO. This resulted in the rapid reduction
of [cGMP]i, inferring a consistently active sGC, as well as ele-
vated phosphodiesterase activity (Figure 4C). The PDE5-specific
inhibitor, tadalafil, was next applied to implicate PDE5 as the
major phosphodiesterase inVSM. Despite ODQ inhibition of sGC,
[cGMP]i remained elevated in the presence of tadalafil and sus-
tained NO (Figure 4D). We noted that the detection limitation of
δ-FlincG prevented any further increase in [cGMP]i fluorescence
during the simultaneous inhibition of sGC and PDE5. Neverthe-
less, since a lack of cGMP degradation was seen in Figure 4D as
compared to Figure 4C, it can be concluded that not only is sGC
FIGURE 4 | sGC and PDE5 simultaneously regulate [cGMP]i. Repeated
pulses of 5 nM NO using (A) MAHMA/NO (200 nM+50µM CPTIO, n=5)
and (B) DEA/NO (400 nM+50µM CPTIO, n=6). Shown is the average
mean value and standard deviation of FlincG-transfected VSM cells for
several experiments in red, calculated NO concentration in blue. (C,D)
Representative traces depicting decreased [cGMP]i upon 10µM ODQ
application in the presence of clamped 5 nM NO (Spermine/NO, C), n=4
and persistently elevated [cGMP]i upon tadalafil (1µM) and ODQ (10µM)
treatment, n=7 (D).
active throughout the entire application of clamped NO, but PDE5
is simultaneously active, thus both enzymes are required for the
concerted maintenance of [cGMP]i.
MODELING sGC AND PDE ACTIVITIES
In order to elicit the kinetic relationship of sGC and PDE5 to the
dynamic applications of NO and cGMP, we modified a recently
developed model of cGMP regulation in platelets (Roy and Garth-
waite, 2006; Halvey et al., 2009) to specifically reflect VSM cells
(Table 3). As sGC and PDE5 have already been implicated as
key cGMP regulators (Figure 4), the involvement of phospho-
PDE5 (P-PDE5) was scrutinized in regards to the maintenance of
VSM [cGMP]i. To block the phosphorylation of PDE5, we applied
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FIGURE 5 | Effects of PKG and PDE5 inhibition on cGMP. (A) Averaged
trace of mean cGMP as measured by FlincG in response to 5 nM NO
(MAHMA/NO, black) and the PKG-specific inhibitor, DT-2, treated 5 nM NO
peak (1µM, gray) each normalized to percent maximal F/F0 ratio. (B)
Application of the PDE5-specific inhibitor, tadalafil (1µM). Shown is the
average mean value, n=8.
DT-2, a membrane-permeable and specific inhibitor of PKG1α
(Dostmann et al., 2000; Nickl et al., 2010). NO-induced cGMP
transients (5 nM NO pulse, MAHMA/NO) elicited in the presence
of DT-2 were markedly broader (∼20–30% increase as measured
by peak width and area under the curve; Figure 5A; Table 2),
attributing the phosphorylated PDE5 as a key manager of VSM
[cGMP]i. Phosphorylated PDE5 has been shown by us and others
to remain elevated upon NO stimulation for up to 1 h, implicat-
ing a possible role for P-PDE5 as a long-term phosphodiesterase
(Mullershausen et al., 2001, 2003; Rybalkin et al., 2002; Cawley
et al., 2007; Halvey et al., 2009). We have previously shown a small
but significant increase in baseline cGMP upon application of
the PDE5 inhibitor, sildenafil, suggesting a basal activity of PDE5,
likely due to P-PDE5, which may remain active for over an hour
(Rybalkin et al., 2002; Cawley et al., 2007). Tadalafil was used here
over sildenafil due to the enhanced specificity of tadalafil for PDE5
(Bischoff, 2004). Tadalafil also produced a minor increase in base-
line cGMP (4.4± 1.1% F/F0, n= 8; Figure 5B), lending support
to the presence of P-PDE5 in the absence of NO exposure.
Our VSM-specific model was determined to require the inclu-
sion of an additional non-cGMP activated PDE, likely PDE1,
which has been shown to be present in VSM cells (Rybalkin
et al., 1997, 2002), was found to be necessary to account for
the rapid degradation phases of cGMP illustrated in Figures 1A
and 4A,B (Table 2). The lack of further increase upon tadalafil
treatment (Figure 5B) under constant sGC baseline activation
also suggested the presence of a second PDE not regulated by
cGMP. Finally, a comprehensive model for cGMP modulation in
VSM cells was compiled through the use of previously published
affinity and activity rates of sGC, PDE5, P-PDE5, and PDE1 (see
Table 3) and analysis of our own data to calculate values specific
for VSM cells using cGMP peaks elicited by multiple NO donors
(Figures 2 and 3), the decay of cGMP following ODQ applica-
tion (Figure 4C). Values were solved by establishing the minimal
sum of squares of the errors between the modeled and experimen-
tal cGMP concentrations to solve for the rates of sGC activity as
well as phosphorylated and de-phosphorylated PDE5 (Table 3, see
Methods). Remarkably, this VSM-specific global model precisely
portrays global biosensor-derived cGMP dynamics (Figure 6).
Here, the NO donors exemplified by a wide range of NO release
Table 2 |The effect of P-PDE5 on cGMP peaks.
Donor cGMP P1/2 A.U.C.
MAHMA/NO 135±9.4 (11) 13610±1685 (11)
DT-2+MAHMA/NO 175±21.4 (6) 16776±2259 (6)
30% increase 23% increase
Measurement parameters of MAHMA/NO-induced cGMP peaks with and with-
out P-PDE5 through PKG inhibition by DT-2 by measuring peak width at half-
maximal stimulation (cGMP P1/2) and area under the curve (A.U.C.).
rates were equally modeled to portray internal cGMP concentra-
tions as measured by FlincG. The close match of the modeled trace
with the measured cGMP supports our model for VSM [cGMP]i
dynamics. In addition, the behavior of pulsed (Figures 7A,C)
and clamped (Figures 7B,D) NO, spanning a 40,000-fold dif-
ference in release rates, are simulated with strong accuracy. Also
of note, the enzyme activities determined for the Vmax for sGC
and PDE5 (0.19± 0.06µM s−1 and 75± 3 nM s−1, respectively;
Table 3) were calculated to be significantly lower than that for
platelets [130 and 125µM s−1, respectively (Halvey et al., 2009)].
This relatively low enzyme activity is likely accounted for by a low
expression of sGC, similar to that seen in GClowPDEHEK cells as
previously stated (Batchelor et al., 2010).
THE KINETIC PROFILES OF NO FORMATION AND VASOMOTOR
RESPONSES IN ISOLATED ARTERIES
Since NO appears to control a tight regulation on [cGMP]i, we
next determined if this modulation extends to the regulation of
vasomotor reactivity in intact blood vessels. Cannulated arteries
from anterior rat brain with 80 mmHg intraluminal pressure were
allowed to develop myogenic tone (see Methods). Here, repeated
applications of 5 nM NO pulses (200 nM MAHMA/NO+ 50µM
CPTIO) elicited transient relaxations of small resistance arteries
(Figure 8A; peak width at half-maximum (P1/2)= 150± 26.2 s,
n= 7; 85± 14.5% total maximal relaxation as determined by
Ca2+-free PSS, n= 6; see Methods), similar to those seen in iso-
lated cells (Figures 1A and 2A,B). These transient relaxations were
not only elicited in the absence of CPTIO, but also observed using
other short half-life donors (DEA/NO and PROLI/NO, data not
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Table 3 |The mathematical model parameters and values.
Parameter Value Description
k1 3×10−8 M−1s−1 Activation and deactivation constants of sGC, previously determined
(Garthwaite, 2005; Roy et al., 2008).
k−1 6 s−1
k2, k−2 28 s−1
k3, k4, k5, k6,
k−3,k−4, k−5, k−6
1000 M−1s−1, 200 s−1, 7.34×10−4 M−1s−1, 1 s−1,
100 s−1, 18×10−5 M−1s−1, 4×10−8 s−1, 0.001 s−1
sGC desensitization rates (Halvey et al., 2009)
GCmax 0.19±0.06µM s−1 Maximum sGC velocity
kp1 1.7×104 M−1 s−1 Binding affinity of cGMP for basal PDE5 (Halvey et al., 2009)
kp−1 0.13 s−1
kp2 0.3 s−1 Activation rates of catalytically active PDE5 (Halvey et al., 2009)
kp−2 0.12 s−1
kp3 0.2×105 M−1 s−1 Activation rates of phosphorylated PDE5 (Halvey et al., 2009)
kp−3 2×10−3 s−1
Vp1 Vp2×0.05 Maximum velocity of basal PDE5 (Halvey et al., 2009)
Vp2 75±3 nM s−1 Maximum velocity of active PDE5
Vp3 2×Vp2 Maximum velocity of phosphorylated PDE5 (Corbin et al., 2000)
Vpx 30 nM s−1 Maximum velocity of PDE1
Kp1 3µM Apparent Michaelis constants for basal PDE5, active PDE5, and phos-
phorylated PDE5, respectively (Corbin et al., 2000; Rybalkin et al.,
2003; Halvey et al., 2009).
Kp2 0.351µM
Kp3 0.5× kp2
Kpx 1µM Apparent Michaelis constant for PDE1 (Bender and Beavo, 2006)
The parameters, values, and description of each factor used in the mathematical model of sGC and PDE activity of VSM cells.
shown). The similar peak characteristics for NO-induced vasodi-
lation and [cGMP]i (mean P1/2= 150 s and 135 s, respectively,
Figures 8A and 1A; Table 1) strongly indicate a mechanistic link
between the intracellular signaling cascade and the observed phys-
iology. Likewise, arteries exposed to 5 nM clamped NO (8µM
Spermine/NO+ 60µM CPTIO), exhibited a sustained relaxation
(75.8± 16.5%, maximal relaxation), similar to the [cGMP]i kinet-
ics observed earlier (Figure 8B). Importantly, NO application to
either the chamber or circulating buffer of the myograph setup
resulted in the same transient or sustained vasodilator responses
for either pulsed or clamped NO respectively, indicating these
effects are not an artifact of NO washout, and are in fact due
to the NO donor release rate (see Methods).
Through the unique coupling of clamped NO delivery to small
pressurized arteries and FlincG-transfected single VSM cells, we
report here that the driving force behind vasomotor reactivity
is both the dynamic behavior of NO, as well as its exquisitely
high sensitivity toward sGC specifically in the vasculature. NO
sensitivity of arteries was determined through lumen diameter
measurements in response to application of step-wise steady-
state NO (0.05 to 25 nM NO, Spermine/NO+ 60µM CPTIO;
Figure 9A). The difference of the diameter from baseline for each
NO concentration was normalized to maximal NO-stimulated
relaxation elicited, and an EC50 determined (Figure 9B). The
NO-induced dilation EC50 was observed as 0.42± 0.08 nM
(n= 5), nearly identical to the value obtained in single VSM
cells (0.28± 0.01 nM, Figure 3B), suggesting a strong linkage
of the kinetics and sensitivity of NO between single cells and
whole arteries. To account for the effect of endogenous NO,
this myograph experiment was repeated in the presence of the
eNOS inhibitor l-NNA, with no change on pulsed NO kinet-
ics or EC50 (data not shown). Confirmation of the low EC50
in VSM cells also suggests that the traces obtained using the
FlincG biosensor are a valid and direct indication of the sen-
sitivity of NO for sGC, and not a titration of cGMP to the
indicator.
DISCUSSION
The spatial and temporal regulation of [cGMP]i has become a
recent prime focus in vascular biology (Nausch et al., 2008; Batche-
lor et al., 2010). As cGMP is a critical mediator for the regulation of
vascular relaxation, and therefore blood flow and blood pressure,
understanding how [cGMP]i is managed in VSM cells provides
invaluable information to the molecular mechanisms underlying
vascular physiology. It is widely accepted that the rapid decay of
NO explains the previously observed transient dilations in aor-
tic rings (Ignarro et al., 1987, 1988; Palmer et al., 1987; Amezcua
et al., 1988; Moncada et al., 1991b). Our work further expands this
notion by providing evidence that the enzymes responsible for the
regulation of cGMP have adapted to encompass both pulsed and
sustained exposure to NO in both intact arteries and single VSM
cells (Figures 1, 2, 4, and 8).
Previous attempts to measure sGC potency have used a wide
variety of NO and sGC sources such as purified protein and cellular
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fractions from platelets, aorta homogenates and cerebral fractions
using NO donors and gas, resulting in a wide range of EC50 val-
ues from 0.9 nM to 1.6µM (Stone and Marletta, 1996; Artz et al.,
FIGURE 6 | VSM model predicted cGMP traces for multiple NO donors.
VSM-specific model predicted cGMP (green) and actual cGMP measured by
FlincG (red, averaged traces) after exposure to NO for (A) PROLI/NO, (B)
MAHMA/NO, (C) DEA/NO, and (D) Spermine/NO (FlincG traces are mean
values from Figures 2 and 3).
2001; Bellamy et al., 2002; Wykes and Garthwaite, 2004; Roy and
Garthwaite, 2006; Roy et al., 2008). This report documents the first
application of clamped NO to elicit an EC50 at both the level of
individual cells, as well as intact whole tissue in a physiological set-
ting. The threefold increase in sensitivity to the endogenous sGC
reported here to that of other cell types (i.e., neurons, platelets,
and astrocytes), is likely due to the low level of sGC in VSM as
previously demonstrated (Batchelor et al., 2010). GClowPDEHEK
cells have shown an unprecedented sensitivity to NO, producing
relevant concentrations of cGMP for its downstream kinase, PKG
(Batchelor et al., 2010). The duplication of this sensitivity seen in
VSM cells confirms the need for sub-nanomolar NO activation
of GC to provide a physiological response in vascular tissue. The
confirmation of a low EC50 in isolated VSM cells (Figure 3B) to
that of intact arteries (Figure 9), as well as the previously observed
EC50 of GClowPDEHEK cells (Batchelor et al., 2010; Wood et al.,
2011), revealed that our isolated cell culture system is a sound
reflection of whole tissue physiology. This also suggests that mea-
suring [cGMP]i is a sufficient mechanism to predict the vascular
response. Additionally, the low EC50 is not a reflection of a titration
of the cGMP biosensor, but rather a veritable indication of sGC
potency.
The accuracy of the cGMP-sensor FlincG for determining
cGMP concentration has been recently questioned, as it can
become saturated (Batchelor et al., 2010). δ-FlincG has a dynamic
range of cGMP detection of approximately 20 nM to 2µM
(Nausch et al., 2008). Due to the 2–4µM maximal concentra-
tions of intracellular cGMP (Matchkov et al., 2004), δ-FlincG
has proven to be sensitive enough to capture most of the NO
FIGURE 7 | Modeled sGC, PDE5 and PDE1 activities follow pulsed and
clamped NO. FlincG-monitored cGMP (red) exposed to a 5 nM NO (A,C)
pulse with MAHMA/NO or (B,D) clamp using Spermine/NO are depicted with
the corresponding NO concentrations (blue) and modeled enzymatic activities
of sGC (purple), PDE5 (green) and PDE1 (orange). Enlargement of the first
10 s for pulsed and clamped NO [(A) and (B), respectively].
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FIGURE 8 | NO delivery and vasodilation profiles are correlated in
pressurized cerebral arteries. Cannulated arteries under 80 mmHg were
treated with (A) pulsed NO (200 nM MAHMA/NO+ 50µM CPTIO; n= 7) or
(B) clamped NO (8µM Spermine/NO+60µM CPTIO; n=6), resulting in
repeatable transient or sustained relaxations, respectively.
response. An induction of [cGMP]i could overcome the max-
imal detection level of FlincG and no further increase would
be observed (as in Figure 4D), yet the temporal dynamics of
[cGMP]i below this 2µM limitation will still be very accurately
measured, which has been recently demonstrated (Batchelor et al.,
2010; Wood et al., 2011). All critical measurements of FlincG here
were used sub-maximally to ensure proper quantification. We are
also assured that the biosensor is not saturated through the EC50
shift observed in VSM cells under oxidative stress (Figure 3C).
Together, this provides further evidence for a dynamic kinetic
link between the NO concentration applied and the vasodila-
tory response achieved, with cGMP acting as a direct intracellular
messenger.
While the sensitivity to NO is similar in GClowPDEHEK and
VSM cells and tissue, the mechanism for cGMP regulation was
shown to differ. GClowPDEHEK degrade cGMP by the endoge-
nous PDE, PDE1. VSM cells require not only PDE1, but PDE5
and phospho-PDE5 in order to maintain [cGMP]i, as suggested
by our model and pharmacological studies with the PDE and PKG
inhibitors, sildenafil, tadalafil, and DT-2 (Figures 4 and 5). This
varies greatly from the model of platelet and astrocyte [cGMP]i in
which P-PDE5 does not show a further effect on cGMP degrada-
tion and does not require PDE1 (Halvey et al., 2009). Interestingly,
FIGURE 9 | Sensitivity of sGC to steady-state NO in VSM cells and
pressurized mesenteric arteries. (A) Representative myograph trace of a
cannulated mesenteric artery with myogenic tone exposed to step-wise
increases of clamped NO (0.05–2µM). (B) NO dose-response curve
derived from multiple NO exposed arteries (n=5). EC50s are calculated
from individual myograph traces, then averaged (see Methods).
the activity of VSM PDEs is twice that of GClowPDEHEK (see
Table 3), leading to more rapid cGMP transients; a critical action
in order to maintain a homeostatic vascular dynamic.
With the high prevalence of vascular diseases such as hyperten-
sion, erectile dysfunction and stroke (NIH, 2011; WHOIS, 2011),
a full understanding of the kinetic relationship of the NO/cGMP
signaling pathway may provide essential therapeutic targets for the
treatment, and perhaps prevention, of these diseases.
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